Asymptote to commercialize in clinic cell therapy thawing tech

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Cell therapy catapult, Cgt catapult, Technology, Viral vector

Asymptote plans to launch a point-of-care thawing system for cell therapies it developed with Cell and Gene Therapy Catapult (CGTC).

The commercialization plan was announced this week along with details of a licensing deal that grants Asymptote rights to the intellectual property (IP) underpinning the tech.

Magdalena Blanco, Programme Manager, CGTC told us “Asymptote and CGT Catapult entered into a collaboration agreement last year to co-develop this technology. After one year, the technology is mature enough and CGT has licensed out the IP rights​.”

Despite being a collaboration, development of the vial and bag technologies on which the thawing systems are based was funded by CGT which owns the IP.

Blanco said under the agreement Asymptote has “rights to commercialise these units worldwide as it’s a worldwide, exclusive and royalty bearing license​.”

Asymptote CEO John Morris said: “We are now preparing for commercial launch of the new devices with the first in the family expected to be on the market before the end of the year.

We see this technology as a big step forwards for the cell and gene therapy industry as it fills in an important gap in the cryochain, helping to guarantee cell-based therapies reach patients in perfect condition for an effective treatment​” he said.

Capacity and tech

CGTC – which used to known as Cell Therapy Catapult – was set up by Government Agency Innovate UK in 2012 to help grow the UK’s cell and gene therapy industry.

In addition to providing developers with capacity to test production processes, the organisation also tasked creates enabling technologies. Another recently announced project was the development of a low-cost viral vector production platform with Sympromics​.

All technologies developed by CGTC will be available to the biopharma firms that work with the organisation.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more